The sequenced treatment alternatives to relieve depression (STAR*D): A first look at the initial pharmacotherapy results

Clinical Neuropsychiatry

Volumn 3, Issue 4, 2006, Pages 265-267

  Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDITORIAL; HAMILTON SCALE; HUMAN; MENTAL HEALTH CARE; MONOTHERAPY; PATIENT CARE; PREDICTION; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33845459246     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (2001). Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of Clinical Psychiatry 62, 6, 448-452.
2. Bouwer C, Stein DJ (1997). Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. South African Medical Journal 87, 4 Suppl, 534-537, 540.
3. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P (2006). Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology (Epub: May 12) 1-11.
4. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH (2006). A comparison of mirtazapine and nortriptyline following a two consecutive failed medication treatments for depressed outpatients: a STAR*D report. American Journal of Psychiatry 163, 7, 1161-1172.
5. Joffe RT, Schuller DR (1993). An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Journal of Clinical Psychiatry 54, 7, 269-271.
6. Poirier MF, Boyer P (1999). Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry 175, 12-16.
7. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clinical Trials 25, 1, 119-142.
8. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 12, 1231-1242.
9. Szegedi A, Muller M J, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry 64, 4, 413-420.
10. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006a). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 1, 28-40.